Abstract
We present a therapeutic drug monitoring (TDM) feasibility study using a label-free surface-enhanced Raman spectroscopy (SERS)-based assay for quantifying methotrexate (MTX) from samples collected from children with acute lymphoblastic leukemia undergoing high-dose MTX therapy. We show that, when combined with an appropriate sample preparation (solid phase extraction) and multivariate data analysis (partial least squares regression), the SERS assay demonstrated a good correlation with a reference chromatographic method (r = 0.889, p < 0.005). We also found that the SERS-based approach underestimated MTX concentration, with a 10% bias calculated, but both methods showed similar variability (RSD of 8.4% for HPLC and 11.6% for SERS). The presented results are strong evidence that SERS can be used for TDM of MTX, and this work brings us one step closer to implementing a SERS-based assay in clinics.
Original language | English |
---|---|
Article number | 100649 |
Journal | Sensing and Bio-Sensing Research |
Volume | 44 |
Number of pages | 7 |
ISSN | 2214-1804 |
DOIs | |
Publication status | Published - 2024 |
Keywords
- Chemometrics
- Method comparison
- Methotrexate (MTX)
- SERS
- Silver nanopillars (AgNPs)
- Therapeutic drug monitoring (TDM)